Literature DB >> 7793857

Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits.

R Nau1, T Schmidt, K Kaye, J L Froula, M G Täuber.   

Abstract

Using a rabbit model of pneumococcal meningitis, we compared the pharmacokinetics and bactericidal activities in cerebrospinal fluid (CSF) of older (ciprofloxacin, ofloxacin) and newer (levofloxacin, temafloxacin, CP-116,517, and Win 57273) quinolones with those of the beta-lactam ceftriaxone. All quinolones penetrated into the inflamed CSF better than ceftriaxone, and the speed of entry into CSF was closely related to their degrees of lipophilicity. At a dose of 10 mg/kg.h, which in the case of the quinolones already in use in clinical practice produced concentrations attainable in the sera and CSF of humans, ciprofloxacin had no antipneumococcal activity (delta log10 CFU/ml.h, +0.20 +/- 0.14). Ofloxacin (delta log10 CFU/ml.h, -0.13 +/- 0.12), temafloxacin (delta log10 CFU/ml.h, -0.19 +/- 0.18), and levofloxacin (delta log10 CFU/ml.h, -0.24 +/- 0.16) showed slow bactericidal activity (not significantly different from each other), while CP-116,517 (delta log10 CFU/ml.h, -0.59 +/- 0.21) and Win 57273 (delta log10 CFU/ml.h, -0.72 +/- 0.20) showed increased bactericidal activities in CSF that was comparable to that of ceftriaxone at 10 mg/kg.h (delta log10 CFU/ml.h, -0.80 +/- 0.17). These improved in vivo activities of the newer quinolones reflected their increased in vitro activities. All quinolones and ceftriaxone showed positive correlations between bactericidal rates in CSF and concentrations in CSF relative to their MBCs. Only when this ratio exceeded 10 did the antibiotics exhibit rapid bactericidal activities in CSF. In conclusion, in experimental pneumococcal meningitis the activities of new quinolones with improved antipneumococcal activities were comparable to that of ceftriaxone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793857      PMCID: PMC162589          DOI: 10.1128/AAC.39.3.593

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci.

Authors:  P F Viladrich; F Gudiol; J Liñares; G Rufi; J Ariza; R Pallares
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

2.  Successful treatment of Pseudomonas ventriculitis with ciprofloxacin.

Authors:  D Isaacs; M P Slack; A R Wilkinson; A W Westwood
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

3.  Evaluation of pefloxacin in experimental Escherichia coli meningitis.

Authors:  A M Shibl; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Ciprofloxacin for Pseudomonas aeruginosa meningitis.

Authors:  M R Millar; M A Bransby-Zachary; D S Tompkins; P M Hawkey; R Myles Gibson
Journal:  Lancet       Date:  1986-06-07       Impact factor: 79.321

5.  Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae.

Authors:  M G Täuber; C A Doroshow; C J Hackbarth; M G Rusnak; T A Drake; M A Sande
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

6.  Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits.

Authors:  C J Hackbarth; H F Chambers; F Stella; A M Shibl; M A Sande
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

7.  Cephalosporin antibiotics in therapy of experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis in rabbits.

Authors:  M A Sande; R J Sherertz; O Zak; L J Strausbaugh
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

Review 8.  The mode of action of 4-quinolones and possible mechanisms of resistance.

Authors:  J T Smith
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits.

Authors:  M G Täuber; C J Hackbarth; K G Scott; M G Rusnak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

10.  Rifampin for therapy of experimental pneumococcal meningitis in rabbits.

Authors:  R Nau; K Kaye; M Sachdeva; E R Sande; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more
  29 in total

1.  Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.

Authors:  J Gerber; A Smirnov; A Wellmer; J Ragheb; J Prange; E Schütz; K Wettich; S Kalich; R Nau
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Evaluation of T-3811ME (BMS-284756), a new des-F(6)-quinolone, for treatment of meningitis caused by penicillin-resistant Streptococcus pneumoniae in rabbits.

Authors:  Masahiro Takahata; Hiroshi Yamada; Teiichi Morita; Shinichi Furubou; Shinzaburo Minami; Yozo Todo; Yasuo Watanabe; Hirokazu Narita
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model.

Authors:  D Rodoni; F Hänni; C M Gerber; M Cottagnoud; K Neftel; M G Täuber; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis.

Authors:  Marija Djukic; Tobias Böttcher; Andreas Wellmer; Joachim Gerber; Viola V Brocke; Helmut Eiffert; Roland Nau
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  Brain abscess in a rhesus macaque (Macaca mulatta) with a cephalic implant.

Authors:  Mathias Leblanc; Kristy Berry; Holly McCort; Jon D Reuter
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

Review 6.  Estimation of steady state antibiotic concentration in cerebrospinal fluid from single-dose kinetics.

Authors:  R Nau; H W Prange
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

7.  In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

Authors:  K P Klugman; T Capper; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.

Authors:  R Nau; M Kinzig-Schippers; F Sörgel; S Schinschke; R Rössing; C Müller; H Kolenda; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

9.  Moxifloxacin in the therapy of experimental pneumococcal meningitis.

Authors:  H Schmidt; A Dalhoff; K Stuertz; F Trostdorf; V Chen; O Schneider; C Kohlsdorfer; W Brück; R Nau
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors:  P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.